Northwire Canada EditionTuesday, August 25, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0% GOLD 4697.80 +0.4% SILVER 68.59 −1.4% COPPER 6.61 +0.3% OIL 85.01 −2.4% PALLADIUM 1359.75 +0.7% NVO 0.070 +0.0% SRA 0.780 +0.0% TUK 0.020 −20.0% GWM 0.610 −4.7% MINE 0.110 +0.0% EGM 0.100 +0.0% IRO 1.11 +2.8% CBR 1.41 +2.5% CTN 0.045 +0.0% GMX 2.06 +2.0% NPR 0.700 −2.8% CGD 1.28 +8.5% CRE 0.390 +13.0% PE 0.250 +0.0% PER 0.150 +7.1% SVRS 0.540 +8.0%
Earnings Material +

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026

Nxera Pharma Turns Profitable on Milestone Surge, But Cash Burn Raises Liquidity Questions

By The Northwire Desk — AI Analysis May 01, 2026 · 02:36 4565
Executive Summary
  • Nxera Pharma reported Q1 2026 consolidated results showing a net profit of JPY 1,793 million (US$11.4 million), reversing a net loss of JPY 760 million in the prior year period.
  • Revenue increased to JPY 11,256 million (US$71.7 million), driven by seven R&D milestone events including US$22.5 million from Neurocrine Biosciences and US$10 million from AbbVie.
  • Eli Lilly announced an agreement to acquire Centessa Pharmaceuticals for up to $7.8 billion; Nxera retains rights to future royalties on the OX2R agonist series and holds an equity stake in Centessa.
  • Santhera Pharmaceuticals licensing deal for vamorolone (AGAMREE) in Japan/APAC was finalized, with upfront consideration of US$40 million (US$30m cash + US$10m equity).
  • Cash and cash equivalents decreased to JPY 11,597 million (US$72.6 million) from JPY 20,365 million at the end of FY2025.
  • R&D expenses decreased by JPY 780 million year-over-year due to streamlined focus and program maturation.
Material Impact
  • The shift from net loss to net profit is a fundamental improvement in financial health, validating the company's restructuring efforts announced in late 2025.
  • Revenue growth is heavily reliant on milestone recognition rather than organic product sales alone; while positive, this revenue stream can be lumpy and non-recurring compared to steady commercial sales.
  • The Eli Lilly/Centessa acquisition validates Nxera's discovery platform (NxWave/NxStaR) but does not directly inject capital into Nxera beyond existing royalty/equity rights.
  • The significant drop in cash position (approx. JPY 8.7 billion decrease in one quarter despite profitability) is a critical risk factor that requires scrutiny regarding capital allocation or debt servicing.
  • Regulatory approvals for daridorexant (QUVIVIQ) in Taiwan and MAA submission in South Korea expand the commercial runway, supporting long-term revenue visibility.
4565 · Price
Company Overview
  • Nxera Pharma is a specialty pharmaceutical company focused on developing innovative medicines, primarily leveraging its GPCR-targeted platforms (NxWave™, NxStaR™).
  • Flagship commercial product: QUVIVIQ® (daridorexant), a dual orexin receptor antagonist for insomnia, marketed in Japan via Shionogi and expanding to APAC regions.
  • Other key assets include PIVLAZ® (for rare endocrine disorders) and vamorolone (AGAMREE®) licensed from Santhera for Duchenne Muscular Dystrophy.
  • Proprietary pipeline includes an oral GLP-1 agonist and multiple GPCR programs in oncology and neurology.
Read the original news release →

More from

Jun 30, 2026 · 04:27

AI-driven GPCR drug discovery platform monetizing partnerships while transitioning to a profitable specialty pharma model in APAC.

Other Jun 10, 2026 · 02:35

AI-driven GPCR drug discovery platform accelerates pipeline through strategic consortium membership and milestone-driven revenue turnaround.

M&A / Property Jun 01, 2026 · 19:30

Nxera Accelerates Vamorolone Rollout in South Korea as APAC Specialty Pharma Strategy Gains Traction

Regulatory May 11, 2026 · 02:34

GPCR spin-out reels in $275M in biobucks and equity, keeping Asia rights and cash burn in check

M&A / Property May 08, 2026 · 06:26

Nxera Pharma Defends Core IP Amidst Profitability Turnaround

Regulatory Apr 20, 2026 · 02:30

Nxera Pharma Milestone Payments Offset Cash Burn as Pipeline Validation Accelerates in APAC and US

Other